These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38580503)

  • 1. Health-related quality of life (HRQoL) in German early benefit assessment: The importance of disease-specific instruments.
    Kramer L; Moos M; Thaa B; Welte R; Esser M
    Z Evid Fortbild Qual Gesundhwes; 2024 May; 186():1-9. PubMed ID: 38580503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
    Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.
    Ruof J; Knoerzer D; Dünne AA; Dintsios CM; Staab T; Schwartz FW
    Health Policy; 2014 Nov; 118(2):242-54. PubMed ID: 25194474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and acceptance of electronic quality of life assessment in general practice: an implementation study.
    Rogausch A; Sigle J; Seibert A; Thüring S; Kochen MM; Himmel W
    Health Qual Life Outcomes; 2009 Jun; 7():51. PubMed ID: 19493355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
    Blome C; Augustin M; Metin H; Lohrberg D
    Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
    Staab T; Isbary G; Amelung VE; Ruof J
    BMC Health Serv Res; 2016 Nov; 16(1):651. PubMed ID: 27842592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Involvement of scientific societies in early benefit assessment: Simulated participation or valuable additional input?].
    Bleß HH; Seidlitz C; Ohlmeier C; de Millas C
    Z Evid Fortbild Qual Gesundhwes; 2018 Feb; 130():49-57. PubMed ID: 29103831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Health-Related Quality of Life in the Context of Early Benefit Assessment of Drugs According to § 35a of the German Social Code Book V: A Challenging Endpoint for all the Involved Stakeholders].
    Bender H; Dintsios CM
    Gesundheitswesen; 2018 Feb; 80(2):132-143. PubMed ID: 27846666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
    Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
    Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities to improve the adoption of health-related quality of life evidence as part of the French Health Technology Assessment process.
    Larose H; Lee M; Grueger J; Anota A; Naïditch N; Falissard B; Di Palma M; Chassany O; Khalfallah-Neelz L; Palazuelos-Muñoz S; Tetafort A
    Health Res Policy Syst; 2023 Dec; 21(1):137. PubMed ID: 38115078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach.
    Lohrberg D; Augustin M; Blome C
    Qual Life Res; 2016 Feb; 25(2):447-455. PubMed ID: 26242250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The relevance of quality of life for the work of the Federal Joint Committee].
    Klakow-Franck R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(2-3):151-6. PubMed ID: 24780714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
    Ruof J; Flückiger O; Andre N
    Drugs R D; 2015 Sep; 15(3):221-6. PubMed ID: 26286202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring health related quality of life (HRQoL) in community and facility-based care settings with the interRAI assessment instruments: development of a crosswalk to HUI3.
    Hirdes JP; Bernier J; Garner R; Finès P; Jantzi M
    Qual Life Res; 2018 May; 27(5):1295-1309. PubMed ID: 29435802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
    Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
    Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
    Fischer KE; Stargardt T
    Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.